Jazz Pharmaceuticals plc (JAZZ) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-03
(Q2 2026)
— full calendar
Earnings Reports
-
Jazz Pharmaceuticals (JAZZ) Q1 2026: Oncology Revenue Jumps 45%, Pipeline Readies for GEA Launch
May 06, 2026
-
Jazz Pharmaceuticals (JAZZ) Q4 2025: Rare Oncology and Epilepsy Revenues Surge to $2.2B, Offsetting Sleep Franchise Headwinds
February 25, 2026
-
Jazz Pharmaceuticals (JAZZ) Q3 2025: ZyWave Grows 11% as Generic Threat Looms for Sleep Franchise
November 06, 2025
-
Jazz Pharmaceuticals (JAZZ) Q2 2025: ZyWave Patient Adds Drive 13% Growth in Sleep Franchise as Oncology Awaits PDUFA Milestones
August 06, 2025